LONDON, UNITED KINGDOM / ACCESSWIRE / July 10, 2024 / TR-1: Standard form for notification of major holdings
|
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i |
||||||
|
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: |
Poolbeg Pharma PLC |
|||||
|
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) |
||||||
|
Non-UK issuer |
||||||
|
2. Reason for the notification (please mark the appropriate box or boxes with an “X”) |
||||||
|
An acquisition or disposal of voting rights |
X |
|||||
|
An acquisition or disposal of financial instruments |
||||||
|
An event changing the breakdown of voting rights |
||||||
|
Other (please specify)iii: |
||||||
|
3. Details of person subject to the notification obligationiv |
||||||
|
Name |
Michael Kelly |
|||||
|
City and country of registered office (if applicable) |
||||||
|
4. Full name of shareholder(s) (if different from 3.)v |
||||||
|
Name |
||||||
|
City and country of registered office (if applicable) |
||||||
|
5. Date on which the threshold was crossed or reachedvi: |
4 July 2024 |
|||||
|
6. Date on which issuer notified (DD/MM/YYYY): |
9 July 2024 |
|||||
|
7. Total positions of person(s) subject to the notification obligation |
||||||
|
% of voting rights attached to shares (total of 8. A) |
% of voting rights through financial instruments |
Total of both in % (8.A + 8.B) |
Total number of voting rights held in issuervii |
|||
|
Resulting situation on the date on which threshold was crossed or reached |
5.2% |
5.2% |
26,039,455 |
|||
|
Position of previous notification (if applicable) |
4.8% |
|||||
|
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii |
||||
|
A: Voting rights attached to shares |
||||
|
Class/type of ISIN code (if possible) |
Number of voting rightsix |
% of voting rights |
||
|
Direct (DTR5.1) |
Indirect (DTR5.2.1) |
Direct (DTR5.1) |
Indirect (DTR5.2.1) |
|
|
GB00BKPG7Z60 |
26,039,455 |
5.2% |
||
|
SUBTOTAL 8. A |
26,039,455 |
5.2% |
||
|
B 1: Financial Instruments according to DTR5.3.1R (1) (a) |
||||
|
Type of financial instrument |
Expiration |
Exercise/ |
Number of voting rights that may be acquired if the instrument is exercised/converted. |
% of voting rights |
|
SUBTOTAL 8. B 1 |
||||
|
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b) |
|||||
|
Type of financial instrument |
Expiration |
Exercise/ |
Physical or cash settlementxii |
Number of voting rights |
% of voting rights |
|
SUBTOTAL 8.B.2 |
|||||
|
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”) |
||||
|
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii |
||||
|
Full chain of controlled undertakings through which the voting rights and/or the |
X |
|||
|
Namexv |
% of voting rights if it equals or is higher than the notifiable threshold |
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold |
Total of both if it equals or is higher than the notifiable threshold |
|
|
Michael Kelly |
||||
|
10. In case of proxy voting, please identify: |
||||
|
Name of the proxy holder |
||||
|
The number and % of voting rights held |
||||
|
The date until which the voting rights will be held |
||||
|
11. Additional informationxvi |
||||
|
Place of completion |
Dublin, Ireland |
|
Date of completion |
9 July 2024 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Poolbeg Pharma PLC
View the original press release on accesswire.com
View the original press release on accesswire.com
Providing researchers with unparalleled opportunity to access novel endpoints LONDON, July 10, 2024 /PRNewswire/ -- Healthcare…
BLYTH, England, July 10, 2024 /PRNewswire/ -- On the fiftieth anniversary of the main piece…
Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases HAMBURG,…
GOTHENBURG, SWEDEN / ACCESSWIRE / July 10, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July…
WESTLAKE, Texas, July 9, 2024 /PRNewswire/ -- AvodahMed is pleased to announce the appointment of…
ALLENTOWN, Pa., July 9, 2024 /PRNewswire/ -- HNL Lab Medicine is excited to announce the…